Thus, in addition to its ability to reduce the activity of wild-type RAC1 and cancer-associated RAC1 P29S and RAC1b, A41 may also be able to reduce a range of situations where RAC1 is upregulated by GEF mutations in cancers. Here, RAC1 is linked to cancer.